

GI Division Research Grand Rounds

GI Division Research Grand Rounds - 5/21/2025

Online

May 21, 2025 – 7:30 AM

Learning Objectives

Upon completion of this session, learners should be able to:

- 1 Identify techniques to improve the number of people being screened for colon cancer and the skills to improve the quality of screening.
- 2 Explain the treatment of Hepatitis C by addressing gaps in the optimal drug regimen for its effective eradication, despite significant advancements in recent years.
- 3 Recognize the most cost-efficient use of biological agents in the management of Inflammatory Bowel Disease (IBD) as treatment strategies evolve.
- 4 Identify achalasia patients and streamline pre, peri, and post-treatment outcomes, reflecting the evolved treatment approaches for achalasia.

Target Audience

Specialties – Gastroenterology/Hepatology

Professions – Physician, Fellow/Resident, Nurse, Other, Physician Assistant, Scientist / Researcher

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credits*[™] issued by organizations accredited by the ACCME. For relicensure, the California Board of Registered Nursing accepts *AMA PRA Category 1 Credits*[™].

Disclosure Statement

All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Rena Yadlapati, MD	Faculty	Consulting Fee-Phathom Pharmaceuticals Consulting Fee- Braintree Stocks or stock options,

		excluding diversified mutual funds-RJS Mediagnostix - 12/03/2024
Alyssa Lorenzo, N/A	Activity Coordinator	Nothing to disclose - 02/13/2025
Syed Fehmi, MD, Professor	Course Director	Nothing to disclose - 03/25/2025
Joshua Rubin, MD	Co-Director	Nothing to disclose - 03/24/2025
Maryam Zafer, MD, MPH	Faculty	Nothing to disclose - 10/28/2024

Acknowledgment of Commercial Support

This session has received no commercial support.